Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Adaptability of Antibody-Coupled T Cell Receptor (ACTR) Engineered Autologous T Cells in Combination with Daratumumab over CAR-Based Approaches

Taylor Hickman, BS, Adrianna Graziano, Katie O'Callaghan, PhD, Ryan Boomer, BA, Eugene Choi, MS, Allison Nelson, BS, Greg Motz, PhD, Jessica Sachs, MD, Birgit Schultes, PhD, Seth Ettenberg, PhD, Tooba Cheema, PhD

Blood (2017) 130 (Supplement 1): 3189.

https://doi.org/10.1182/blood.V130.Suppl_1.3189.3189

Published: 2017

Journal Articles

ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-Cell Receptors (ACTR), Induces Complete Responses in Patients with Relapsed or Refractory CD20-Positive B-Cell Lymphoma, in Combination with Rituximab

Luke Paul Akard, MD, Samantha Jaglowski, MD, Steven M. Devine, MD, Matthew S. McKinney, MD, Michael Vasconcelles, MD, Heather Huet, PhD, Seth Ettenberg, PhD, Ann Ranger, PhD, Jeremy S. Abramson, MD MMSc

Blood (2017)

https://doi.org/10.1182/blood.V130.Suppl_1.580.580

Published: 2017

Journal Articles

Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma

Rao H Prabhala, PH.D., Mariateresa Fulciniti, PhD, Dheeraj Pelluru, PhD, Puru Nanjappa, MS, Christine Pai, BS, Saem Lee, B.A., Nithya Prabhala, Weihua Song, MD, Constantine S. Mitsiades, MD, PhD, Konstantinos Lefkimmiatis, PhD, Yu-Tzu Tai, PhD, Irene Ghobrial, MD, Paul Richardson, MD, John Daley, Kenneth C. Anderson, MD, Seth Ettenberg, Franco Di Padova, Nikhil C. Munshi, MD

Blood (2010) 116 (21): 456.

https://doi.org/10.1182/blood.V116.21.456.456

Published: 2010

Journal Articles

A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).

Swaminathan Padmanabhan, MD, MBBS, Joseph Thaddeus Beck, MD, Kevin R. Kelly, MD, Nikhil C. Munshi, MD, Andy Dzik-Jurasz, Esha Gangolli, Seth Ettenberg, Kelly Miner, Sanela Bilic, Winston Whyte, Fazal Mehdi, Lu-May Chiang, Patricia Liz Rae, BSc, Andrew Spencer, Jatin Shah, MD, Kenneth C. Anderson, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, A. Keith Stewart, MBChB

Blood (2009) 114 (22): 750.

https://doi.org/10.1182/blood.V114.22.750.750

Published: 2009

Journal Articles

Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic for Multiple Myeloma.

Mariateresa Fulciniti, PhD, Pierfrancesco Tassone, MD, Teru Hideshima, MD, Sonia Vallet, MD, Seth Ettenberg, PhD, David Stover, PhD, Simona Blotta, MD, Zhenxin Shen, PhD, Maria Teresa Dimartino, PhD, Paola Neri, MD, Rao Prabhala, PhD, Raje Nopur, MD, Steven R. Goldring, MD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2007) 110 (11): 551.

https://doi.org/10.1182/blood.V110.11.551.551

Published: 2007

NARROW

Adaptability of Antibody-Coupled T Cell Receptor (ACTR) Engineered Autologous T Cells in Combination with Daratumumab over CAR-Based Approaches

ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-Cell Receptors (ACTR), Induces Complete Responses in Patients with Relapsed or Refractory CD20-Positive B-Cell Lymphoma, in Combination with Rituximab

Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma

A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).

Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Adaptability of Antibody-Coupled T Cell Receptor (ACTR) Engineered Autologous T Cells in Combination with Daratumumab over CAR-Based Approaches

ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-Cell Receptors (ACTR), Induces Complete Responses in Patients with Relapsed or Refractory CD20-Positive B-Cell Lymphoma, in Combination with Rituximab

Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma

A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).

Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only